PDF Roche fact sheet

Roche fact sheet

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience.

Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients.

The Roche innovation network

Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-four medicines developed by Roche are included in the World Health Organisation Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.

In 2014 the Roche Group employed 88,500 people worldwide, invested 8.9 billion Swiss francs in R&D and posted sales of 47.5 billion Swiss francs.

Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

Genentech South San Francisco, CA

Pleasanton, CA Ventana Tucson, AZ

Roche Basel, Switzerland

Chugai Tokyo, Japan

Madison, WI Indianapolis, IN Branford, MA

Penzberg, Germany

Mannheim, Penzberg, Germany

Rotkreuz, Switzerland

Shanghai, China

Roche's capabilities are augmented by technology collaborations and a constellation of worldwide alliances to help develop individual products and entire product portfolios.

Roche has one of the strongest drug development pipelines in the industry with 30 phase III projects and multiple projects currently in registration. The pipeline overall comprises over 60 new potential medicines and over 40 additional indications for existing medicines. Half of the projects in late-stage development utilise a companion diagnostic test and thus could help advance personalised healthcare.

Roche Pharma, including Genentech

Roche Diagnostics

Majority shareholdings

Roche is recognised as a leader in Corporate Governance and Sustainability. Roche is listed on the FTSE4 Good Indices and is the 2014 Super Sector leader for healthcare in the Dow Jones Sustainability Indices (DJSI). Roche participates in various humanitarian and educational projects.

Pharmaceuticals

The pharmaceuticals division is made up of Roche Pharma represented in over 150 countries, Genentech (the Group's US pharma business) and a majority shareholding of Chugai in Japan. Eight of Roche's 10 top-selling medicines are manufactured using biotechnology, and biopharmaceuticals account for more than 70% of pharmaceutical sales.

Global sales of top 10 medicines in 2014

MabThera/Rituxan1,2 Avastin1 Herceptin1 Lucentis3 Tarceva1 Actemra/RoActemra2 Pegasys4 Xolair2 Tamiflu4 Perjeta1

CHF billion

6.9 6.4 6.3 1.7 1.3 1.2 1.0 1.0 1.0 0.9

Sales by therapeutic area 2014

Sales by region 2014

Oncology 62% (+5%) Immunology 14% (+13%) Infectious diseases 9% (+4%)

Ophthalmology 5% (+2%) Neuroscience 2% (-6%) Other 8% (-3%)

United States 43% (+6%) Europe 26% (+3%) Japan 9% (+7%) Eastern Europe, Middle East & Africa 5% (-11%) Latin America 6% (+9%) Asia-Pacific 8% (+4%) Other 3% (+7%)

Diagnostics

Roche Diagnostics is the world leader in in vitro diagnostics; products used to test blood and other body fluids and tissue samples to obtain information for the diagnosis, treatment and monitoring of diseases. Its product portfolio ranges from blood glucose meters for people with diabetes and point-of-care testing devices for use in doctors' offices, to high-throughput analysers for hospitals and commercial diagnostic laboratories. The division also supplies state of the art instruments and reagents for life science research.

Sales by business area 2014

Sales by region 2014

Professional Diagnostics 56% (+8%) Diabetes Care 22% (+1%) Molecular Diagnostics 15% (+6%)

Tissue Diagnostics 7% (+10%)

Europe, Middle East & Africa 45% (+4%) North America 25% (+4%) Asia-Pacific 19% (+15%) Latin America 7% (+13%) Japan 4% (+0%)

Italics = growth rates as measured at constant exchange rates 1 Oncology 2 Immunology 3 Ophthalmology 4 Infectious diseases

Key financials

As reported in Swiss Francs (CHF)

Sales

2014

36.7

10.8 47.5

2013

36.3

10.5

46.8

2012

35.2 10.3

45.5

0

25

Core operating profit

2014

2013

50 17.6

17.9

2012

17.2

0

10

20

Operating free cash flow

2014

15.8

2013

16.4

2012

16.1

0

10

20

CHF billion

Per security data as reported in Swiss Francs (CHF)

Core earnings per share (EPS)

2014

14.29

2013

14.27

2012

13.49

0.00

5.00

10.00

15.00

Dividend per share

2014

8.00

2013

7.80

2012

7.35

0.00

Pharmaceuticals

4.00 CHF

Diagnostics

8.00

Group

Contact information

Investor Relations F. Hoffmann-La Roche Ltd CH-4070 Basel Switzerland Main switchboard: +41 61 688 1111 IR requests: +41 61 688 8880 Fax: +41 61 691 0014 investor.relations@ investors

Karl Mahler +41 61 687 8503 karl.mahler@

Peter Boyle +41 61 688 3894 peter.boyle@

Tamer Farhan +41 61 688 2552 tamer. farhan@

Sabine Borngraeber +41 61 688 8027 sabine.borngraeber@

Bruno Eschli +41 61 687 5284 bruno.eschli@

Birgit Masjost +41 61 688 4814 birgit.masjost@

Investor Relations North America Roche Holdings, Inc. Genentech, Inc. 1 DNA Way South San Francisco CA 94080 USA Main number: +1 650 225 5566 Fax: +1 650 225 8326 rocheirna@

Stefan Foser +1 650 467 2016 foser.stefan@

Nina Goworek +1 650 467 8737 goworek.nina@

Stacy Galvin +1 650 225 4150 galvin.stacy@

Ekaterine Kortkhonjia +1 650 467 5873 kortkhonjia.ekaterine@

Additional information

This document contains certain forward-looking statements. These forward-looking statements may be identified by words such as `believes', `expects', `anticipates', `projects', `intends', `should', `seeks', `estimates', `future' or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this document, among others: (1) pricing and product initiatives of competitors; (2) legislative and regulatory developments and economic conditions; (3) delay or inability in obtaining regulatory approvals or bringing products to market; (4) fluctuations in currency exchange rates and general financial market conditions; (5) uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side effects of pipeline or marketed products; (6) increased government pricing pressures; (7) interruptions in production; (8) loss of or inability to obtain adequate protection for intellectual property rights; (9) litigation; (10) loss of key executives or other employees; and (11) adverse publicity and news coverage.

The statement regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche's earnings or earnings per share for any current or future period will necessarily match or exceed the historical published earnings or earnings per share of Roche.

Copyright ? 3 March 2015 by Roche Investor Relations North America, South San Francisco.

 ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download